Caribou Biosciences (CRBU) Non Operating Income (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Non Operating Income of $1.2 million for Q1 2026, down 59.1% year-over-year from $2.9 million in Q1 2025, and down 15.55% quarter-over-quarter from $1.4 million in Q4 2025.
Caribou Biosciences (CRBU) Non Operating Income (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Non Operating Income for 7 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 59.1% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at -$2.1 million (down 113.15% YoY), while the FY2025 annual figure was -$331000.0, down 101.89% from the prior year.
- Non Operating Income retreated to $1.2 million in Q1 2026 per CRBU's latest filing, from $1.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $5.8 million in Q2 2024 and bottomed at -$6.5 million in Q2 2025.
- Historically, Non Operating Income has averaged $2.3 million across 5 years, with a median of $3.1 million in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 10931.25% — and 2025, when it tumbled 212.34%.
- Caribou Biosciences' Non Operating Income stood at $3.7 million in 2022, then slipped by 14.46% to $3.1 million in 2023, then increased by 7.86% to $3.4 million in 2024, then tumbled by 58.09% to $1.4 million in 2025, then decreased by 15.55% to $1.2 million in 2026.
- Business Quant data shows CRBU's Non Operating Income at $1.2 million in Q1 2026, $1.4 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.42 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | -6.52 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 5.80 Mn |
| Mar 31, 2024 | 4.77 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 4.63 Mn |
| Jun 30, 2023 | 3.35 Mn |
| Mar 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 3.66 Mn |
| Sep 30, 2022 | -110,000.00 |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | 1.77 Mn |
| Dec 31, 2021 | 2.25 Mn |
| Sep 30, 2021 | -2.36 Mn |